Original Research ARTICLE
CD4-blockade can induce protection from peanut-induced anaphylaxis
- 1 Instituto de Medicina Molecular, University of Lisbon, Lisbon, Portugal
- 2 Instituto Gulbenkian de Ciência, Oeiras, Portugal
Monoclonal antibodies (mAb) have been shown effective in inducing immune tolerance in a range of animal models of autoimmunity, allergy, and transplantation. We investigated whether CD4-blockade, effective in inducing transplantation tolerance, could prevent systemic immune responses leading to anaphylaxis. We found that treatment with a non-depleting anti-CD4 mAb could prevent peanut-induced anaphylaxis following subsequent systemic exposure to crude peanut extract (CPE). Furthermore, the effect of CD4-blockade did not interfere with overall immune competence, as anti-CD4 treated mice remained fully competent to respond to unrelated antigens. Protection from anaphylaxis correlated with increased frequency of Foxp3+ regulatory T cells (Treg), and was abrogated following Treg depletion. Taken together our data suggest that activation of T cells by CPE in presence of CD4-blockade leads to Treg expansion that can prevent peanut-induced anaphylaxis.
Keywords: immune tolerance, anaphylaxis, peanut, regulatory T cells, Foxp3, anti-CD4 monoclonal antibody
Citation: Duarte J, Caridade M and Graca L (2011) CD4-blockade can induce protection from peanut-induced anaphylaxis. Front. Immun. 2:56. doi: 10.3389/fimmu.2011.00056
Received: 24 June 2011; Paper pending published: 12 July 2011;
Accepted: 04 October 2011; Published online: 19 October 2011.
Edited by:Stephen Paul Cobbold, University of Oxford, UK
Reviewed by:Alain Le Moine, Université Libre de Bruxelles, Belgium
Hans-dieter Volk, Charité – University Medicine Berlin, Germany
Valerie Julia, INSERM, France
Copyright: © 2011 Duarte, Caridade and Graca. This is an open-access article subject to a non-exclusive license between the authors and Frontiers Media SA, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and other Frontiers conditions are complied with.
*Correspondence: Luis Graca, Instituto de Medicina Molecular, University of Lisbon, Avenida Professor Egas Moniz, 1649-025 Lisbon, Portugal. e-mail: email@example.com